GlassScriptPhysician profile
Allison F Pacheco
NPI 1144207473
$7,538.75
in general payments reported to CMS, 2019-2025
32 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $634 · 2022: $1,759 · 2023: $1,595 · 2024: $1,706 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,119 · Education: $26.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,119.22 |
| Education | $26.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,020.79 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $771.05 | 2021-2025 | Ozempic, Wegovy |
| Fresenius USA Marketing, INC. | $591.78 | 2022-2024 | Velphoro |
| Calliditas Therapeutics US INC. | $516.26 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $400.90 | 2022-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $388.73 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $378.36 | 2022-2025 | Mounjaro |
| Ardelyx, INC. | $339.90 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Abbvie INC. | $334.63 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $329.51 | 2023-2025 | Jynarque |
| Akebia Therapeutics INC | $269.14 | 2021-2025 | Vafseo |
| Abbott Laboratories | $240.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.09 | 2022-2023 | |
| Travere Therapeutics, INC. | $210.82 | 2022-2025 | Filspari |
| Amgen INC. | $187.83 | 2022-2025 | Tavneos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $152.30 | 2024-2025 | Acthar |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $123.12 | 2022 | |
| Vifor Pharma, INC. | $117.83 | 2022-2024 | Veltassa |
| Veloxis Pharmaceuticals, INC. | $117.52 | 2022-2024 | Envarsus |
| E.R. Squibb & Sons, L.L.C. | $110.16 | 2023 | Eliquis |
| Pfizer INC. | $100.28 | 2025 | |
| Dexcom, INC. | $90.91 | 2024 | Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $79.59 | 2024-2025 | Prevymis, Dificid |
| La Jolla Pharmaceutical Company | $76.64 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $60.00 | 2023 | |
| Bolton Medical INC | $47.97 | 2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Opko Pharmaceuticals, LLC | $42.66 | 2021-2024 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $23.68 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $20.85 | 2025 | Ultomiris |
| Renalytix Ai, INC. | $20.12 | 2022 | |
| Amicus Therapeutics, INC. | $17.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.